NCT01976858View on ClinicalTrials.gov

A Phase I Study of 8-week Continuous Treatment With Polyethylene Glycol Loxenatide in Patients With Type 2 Diabetes

PHASE1CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

June 30, 2011

Primary Completion Date

September 30, 2011

Study Completion Date

December 31, 2011

Conditions
Type 2 Diabetes
Interventions
DRUG

PEX168

A injection administered subcutaneously

Trial Locations (1)

Unknown

Beijing tongren hospital, Beijing

All Listed Sponsors
collaborator

Beijing Tongren Hospital

OTHER

lead

Jiangsu HengRui Medicine Co., Ltd.

INDUSTRY

NCT01976858 - A Phase I Study of 8-week Continuous Treatment With Polyethylene Glycol Loxenatide in Patients With Type 2 Diabetes | Biotech Hunter | Biotech Hunter